ORAMED PHARMACEUTICALS INC
For the period ended Aug 1, 2024. Filed Jun 20, 2024.
View on SEC.govAbout this filing
What shareholders are asked to vote on at a company's meeting. It is where to find what directors and top executives are paid, and who owns the most shares.
Aug 1, 2024 · Filed Jun 20, 2024
Use the contents to explore the available documents and sections.
Contents
PAY VERSUS PERFORMANCE TABLE
As required by Section 953(a) of the Dodd-Frank Wall Street Reform and Consumer Protection Act, and Item 402(v) of Regulation S-K, we are providing the following information about the relationship between executive compensation actually paid to our Chief Executive Officer and our other NEOs and certain financial performance of the Company for each of Fiscal 2023, the fiscal year ended December 31, 2022 and the fiscal year ended August 31, 2021. On February 28, 2022, the Board acted to change our fiscal year from a year beginning on September 1 and ending on August 31, to a year beginning on January 1 and ending on December 31.
| Fiscal Year | Summary Compensation Table Total for CEO | Compensation Actually Paid to CEO (1) | Average Summary Compensation Table Total for Other NEOs | Average Compensation Actually Paid to Other NEOs (1) | Value of Initial Fixed $100 Investment Based on Total Shareholder Return | Net Income (Loss) |
|---|---|---|---|---|---|---|
| 2023 | $1,659,222 | $265,813 | $823,071 | $152,260 | $66.19 | $5,088 |
| 2022 | $6,833,620 | $7,447,366 | $2,169,703 | $2,502,120 | $344.70 | $(37,764) |
| 2021 | $4,020,581 | $10,981,233 | $1,310,794 | $2,545,504 | $563.90 | $22,989 |
| (1) | Amounts represent compensation actually paid to the following persons: (a) for 2023 - Mr. Nadav Kidron, our President, Chief Executive Officer and Chairman, Dr. Miriam Kidron, our Chief Scientific Officer and a director, and Mr. David Silberman, our Chief Financial Officer; (b) for 2022 – Mr. Nadav Kidron, our President, Chief Executive Officer and Chairman, Dr. Miriam Kidron, our Chief Scientific Officer and a director, and Mr. David Silberman, our Chief Financial Officer; and (c) for 2021 – Mr. Nadav Kidron, Dr. Miriam Kidron, Mr. David Silberman, Mr. Joshua Hexter, Mr. Michael Rabinowitz and Mr. Avraham Gabay, our former Chief Financial Officer. As determined under SEC rules, the amounts reported in the “Compensation Actually Paid to CEO” and “Compensation Actually Paid to other NEOs” columns do not reflect the actual compensation paid to or realized by our Chief Executive Officer or our other NEOs during each applicable year. The calculation of compensation actually paid for purposes of this table includes point-in-time fair values of stock awards and these values will fluctuate based on our stock price, various accounting valuation assumptions and projected performance related to our performance awards. See “Summary Compensation Table” above for certain other compensation of our Chief Executive Officer and our other NEOs for each applicable fiscal year. |
Compensation actually paid to our Chief Executive Officer represents the total compensation reported in the Summary Compensation Table for the applicable fiscal year, as adjusted as follows:
| Adjustments to Determine Compensation “Actually Paid” to our Chief Executive Officer · 2023 · 2022 · 2021 | ||||
|---|---|---|---|---|
| Total Compensation in the Summary Compensation Table | $1,659,222 | $6,833,620 | $4,020,581 | |
| Deduction for Amounts Reported under the “Stock Awards” Column in the Summary Compensation Table | $(904,920) | $(4,847,380) | $(1,995,666) | |
| Deduction for Amounts Reported under “Option Awards” Column in the Summary Compensation Table | $ | - | $(875,241) | $(876,693) |
| Increase for Fair Value of Awards Granted During Fiscal Year that Remain Unvested as of Year End, Determined as of Applicable Fiscal Year End(1) | $483,368 | $4,583,311 | $3,864,409 | |
| Increase for Fair Value of Awards Granted During Fiscal Year that Vested during Applicable Fiscal Year, Determined as of Vesting Date(1) | $656,078 | $2,367,740 | $1,968,000 | |
| Increase/deduction for Awards Granted During Prior Fiscal Year that were Outstanding and Unvested as of Applicable Fiscal Year End | $(768,999) | $(383,589) | $3,904,373 | |
| Increase/deduction for Awards Granted During Prior Fiscal Year that Vested During Applicable Fiscal Year | $(858,935) | $(231,096) | $96,230 | |
| Total Adjustments | $(1,393,409) | $613,746 | $6,960,652 | |
| Compensation Actually Paid to the CEO | $265,813 | $7,447,366 | $10,981,233 | |
| (1) | All fair value amounts are computed in accordance with Financial Accounting Standards Board (FASB) Accounting Standards Codification (ASC) Topic 718. |
| Adjustments to Determine Compensation “Actually Paid” to our Other Named Executive Officers · 2023 · 2022 · 2021 | ||||
|---|---|---|---|---|
| Average Total Compensation in the Summary Compensation Table | $823,071 | $2,169,703 | $1,310,794 | |
| Deduction for Amounts Reported under the “Stock Awards” Column in the Summary Compensation Table | $(441,330) | $(1,348,993) | $(702,838) | |
| Deduction for Amounts Reported under “Option Awards” Column in the Summary Compensation Table | $ | - | $(425,351) | $(394,179) |
| Increase for Fair Value of Awards Granted During Fiscal Year that Remain Unvested as of Year End, Determined as of Applicable Fiscal Year End(2) | $392,267 | $2,232,407 | $1,390,828 | |
| Increase for Fair Value of Awards Granted During Fiscal Year that Vested during Applicable Fiscal Year, Determined as of Vesting Date | $79,592 | $142,120 | $498,557 | |
| Increase/deduction for Awards Granted During Prior Fiscal Year that were Outstanding and Unvested as of Applicable Fiscal Year End | $(382,367) | $(170,831) | $510,409 | |
| Increase/deduction for Awards Granted During Prior Fiscal Year that Vested During Applicable Fiscal Year | $(318,972) | $(96,935) | $(68,068) | |
| Total Adjustments | $(670,811) | $332,417 | $1,234,710 | |
| Compensation Actually Paid to the Other Named Executive Officers | $152,260 | $2,502,120 | $2,545,504 | |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.